Epilepsy

The Behind the Seizure® program provides no-charge access to Invitae’s comprehensive epilepsy panel for children under 10 with unprovoked seizure onset between ages 2–5. The panel evaluates 300+ epilepsy-related genes that can influence management decisions. Early genetic insights may support faster diagnosis, targeted treatment planning, and improved care coordination.

The Epilepsy Answers Partnership Program provides GeneDx ExomeDx whole exome sequencing for U.S. patients under 18 who had their first unprovoked seizure before age 8. Unlike programs where the sponsor pays the full cost upfront, this is a reimbursement-assurance program: the test is billed to insurance as usual, and the pharmaceutical partners cover the cost when insurance denies the exome claim or the patient is uninsured. Because the test is billed to the payer first, existing reimbursement pathways are unaffected, and providers can enroll all eligible patients, including those with coverage. The program is co-sponsored by Biogen, Praxis Precision Medicines, and Stoke Therapeutics, includes post-test genetic counseling support, and requires consent to the program's mandatory data-sharing practices.